Janssen(强生)COVID-19疫苗的使用:免疫实践咨询委员会更新的临时推荐——美国,2021年12月
2021年12月16日,免疫实践咨询委员会(ACIP)召开紧急会议审查血栓伴血小板减少综合征(TTS)更新数据及获益-风险评估后推荐,对所有≥18岁人群,优先使用mRNA COVID-19疫苗而非Janssen COVID-19疫苗,包括基础免疫和加强针;Janssen COVID-19疫苗可考虑用于某些情况,包括对mRNA COVID-19疫苗有禁忌证者。
要点
- ACIP推荐对所有≥18岁人群优先使用mRNA COVID-19疫苗而非Janssen COVID-19疫苗,包括基础免疫和加强针。
- Janssen COVID-19疫苗可考虑用于某些情况,包括对mRNA COVID-19疫苗有禁忌证者。
- 2021年4月13日CDC与FDA因TTS报告建议暂停使用Janssen COVID-19疫苗,10天后ACIP重申≥18岁人群临时推荐并加入罕见凝血事件警告。
核心结论
- ACIP推荐对所有≥18岁人群优先使用mRNA COVID-19疫苗而非Janssen COVID-19疫苗,包括基础免疫和加强针。
- Janssen COVID-19疫苗可考虑用于某些情况,包括对mRNA COVID-19疫苗有禁忌证者。
研究设计与样本
- 美国免疫实践咨询委员会(ACIP)于2021年12月16日召开紧急会议,审查TTS更新数据及更新的获益-风险评估后作出推荐。
主要发现
- 2021年2月27日FDA对Janssen COVID-19疫苗签发紧急使用授权,2021年2月28日ACIP发布≥18岁人群单剂基础免疫临时推荐。
- 2021年4月13日CDC与FDA在收到TTS报告后建议暂停使用Janssen COVID-19疫苗,TTS表现为低血小板和血栓,包括脑静脉窦血栓形成(CVST)等不常见部位。
- 暂停开始10天后ACIP重申≥18岁人群使用Janssen COVID-19疫苗的临时推荐,但加入接种后罕见凝血事件警告,主要涉及18-49岁女性。
- 2021年7月ACIP审查纳入吉兰-巴雷综合征(GBS)和TTS风险的更新获益-风险评估后认为接种Janssen COVID-19疫苗的获益大于风险。
- 通过持续安全监测和疫苗不良事件报告系统(VAERS)报告审查,发现接种Janssen COVID-19疫苗后更多TTS病例,包括死亡病例。
关键数值与推荐
- ACIP推荐对所有≥18岁人群优先使用mRNA COVID-19疫苗而非Janssen COVID-19疫苗,包括基础免疫和加强针。
- Janssen COVID-19疫苗可考虑用于某些情况,包括对mRNA COVID-19疫苗有禁忌证者。
临床怎么用
- 对所有≥18岁人群,优先使用mRNA COVID-19疫苗而非Janssen COVID-19疫苗,包括基础免疫和加强针。
- Janssen COVID-19疫苗可考虑用于某些情况,包括对mRNA COVID-19疫苗有禁忌证者。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
On February 27, 2021, the Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for the adenovirus-vectored COVID-19 vaccine (Janssen Biotech, Inc., a Janssen Pharmaceutical company, Johnson & Johnson), and on February 28, 2021, the Advisory Committee on Immunization Practices (ACIP) issued an interim recommendation for its use as a single-dose primary vaccination in persons aged ≥18 years (1,2). On April 13, 2021, CDC and FDA recommended a pause in the use of Janssen COVID-19 vaccine after reports of thrombosis with thrombocytopenia syndrome (TTS), a rare condition characterized by low platelets and thrombosis, including at unusual sites such as the cerebral venous sinus (cerebral venous sinus thrombosis [CVST]), after receipt of the vaccine.* ACIP rapidly convened two emergency meetings to review reported cases of TTS, and 10 days after the pause commenced, ACIP reaffirmed its interim recommendation for use of the Janssen COVID-19 vaccine in persons aged ≥18 years, but included a warning regarding rare clotting events after vaccination, primarily among women aged 18-49 years (3). In July, after review of an updated benefit-risk assessment accounting for risks of Guillain-Barré syndrome (GBS) and TTS, ACIP concluded that benefits of vaccination with Janssen COVID-19 vaccine outweighed risks. Through ongoing safety surveillance and review of reports from the Vaccine Adverse Event Reporting System (VAERS), additional cases of TTS after receipt of Janssen COVID-19 vaccine, including deaths, were identified. On December 16, 2021, ACIP held an emergency meeting to review updated data on TTS and an updated benefit-risk assessment. At that meeting, ACIP made a recommendation for preferential use of mRNA COVID-19 vaccines over the Janssen COVID-19 vaccine, including both primary and booster doses administered to prevent COVID-19, for all persons aged ≥18 years. The Janssen COVID-19 vaccine may be considered in some situations, including for persons with a contraindication to receipt of mRNA COVID-19 vaccines.
引用
- Oliver SE, Wallace M, See I, et al. Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine: Updated Interim Recommendations from the Advisory Committee on Immunization Practices - United States, December 2021. MMWR Morb Mortal Wkly Rep. 2022. PMID: 35051137. doi:10.15585/mmwr.mm7103a4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。